Pan-amyloid PET/CT scans to find amyloid deposits in adults
Official title: Pan-Amyloid PET/CT in Various Amyloid-Related Disease
Run by Tianjin Medical University · NCT07130565 · Data updated 2026-11-12
This project tests whether PET/CT scans using amyloid tracers can find amyloid deposits in adults with suspected or known amyloidosis, including heart involvement.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 80 Years |
| Sex | All |
| Enrollment | 500 (estimated) |
| Sponsor | Tianjin Medical University Academic / other |
| Locations | 3 sites (Hefei, Anhui and 2 other locations) |
| Status | Recruiting |
| Started | November 1, 2023 |
| Main results expected | November 1, 2028 |
| Study ends | November 1, 2028 |
| Registry record updated | September 8, 2026 |
| Trial ID | NCT07130565 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (18+) with suspected, newly diagnosed, or previously treated amyloidosis who are scheduled for a pan-amyloid PET/CT scan and can provide informed consent are ideal candidates.
✕Probably not a fit
People who do not have amyloid-related disease, who are pregnant, or who cannot undergo or consent to PET/CT imaging are unlikely to benefit from this protocol.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational imaging effort uses several amyloid PET tracers (including 18F-labeled ligands and 11C-PIB) to image adults with suspected, newly diagnosed, or previously treated amyloidosis. Participants undergo PET/CT (and where available MRI) for initial staging or detection of recurrence, and focal uptake is quantified by SUVmax. The team will calculate sensitivity, specificity, positive and negative predictive values, and overall accuracy of tracer uptake for identifying primary and metastatic amyloid lesions. Imaging is conducted at tertiary centers in China and data are analyzed to characterize diagnostic performance across lesion sites.
Why it matters
Potential benefit: If successful, this approach could help doctors detect and map amyloid deposits throughout the body more accurately, which may guide diagnosis and management.
How similar studies have gone: Previous work with tracers like 11C-PIB and various 18F amyloid ligands has shown promising detection of cerebral and cardiac amyloid, but whole-body (pan-amyloid) imaging is a relatively newer application with mixed but encouraging results.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: \- (i) adult patients (aged 18 years or order); (ii) patients with suspected or new diagnosed or previously treated cardiac amyloidosis (supporting evidence may include MRI, CT, serum markers and pathology report); (iii) patients who had scheduled Pan-Amyloid PET/CT scan; (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee. Exclusion Criteria: \- (i) patients with non-CA lesions; (ii) patients with pregnancy; (iii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.
Where it's running
-
The First Affiliated Hospital of University of Science and Technology of China
Hefei, Anhui, China Recruiting -
The Affiliated Hospital of Qingdao University
Qingdao, Shandong, China Recruiting -
Tianjin Medical University General Hospital
Tianjin, Tianjin Municipality, China Recruiting
Study contacts
- Study coordinator: Haonan Yu, MD
- Email: dreamadam@126.com
- Phone: +8613821000597
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
18F‑FT8 PET imaging for light‑chain (AL) cardiac amyloidosis
This project tests whether a new PET tracer, 18F‑FT8, can safely and clearly image light‑chain (AL) cardiac amyloidosis in adults with suspected or known disease and in healthy volunteers.
-
Testing LY4405094 in healthy people and people with Alzheimer’s disease
This study tests LY4405094 to see if it is safe and how it behaves in the body, including how it reaches the brain fluid in healthy participants and how it affects a brain protein in people with Alzheimer's disease.
-
Test of amyloid-targeting medicines in healthy people and adults with Alzheimer’s
This trial tests the safety and tolerability of amyloid-targeting drugs, plus a placebo, in healthy adults and in people with Alzheimer’s disease to see if the drugs can reduce brain amyloid plaques.
-
Liver and Coagulation Markers in ATTR Cardiac Amyloidosis
This study tests liver function and blood-clotting markers in people with ATTR-CA to see if they reflect disease severity and progression.
-
Acoramidis for ATTR-CM: Cardiac Imaging Study
This study tests whether acoramidis can improve heart structure and function in people with transthyretin amyloid cardiomyopathy.
-
Cardiac Amyloidosis: See if Intracardiac Thrombi are Common on CT
This study tests whether a contrast-enhanced cardiac CT can reliably detect intracardiac thrombi in adults with cardiac amyloidosis.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.